Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer Authors: Jianxin Cai, Jiahua Tu, Ronglong Lin, Jianxin Xu Published: 2026 ABSTRACT AbstractBackgroundSystemic inflammation plays a pivotal role in tumor progression and patient prognosis in non-small cell lung cancer (NSCLC). While preoperative inflammatory biomarkers have demonstrated prognostic utility, the additional value of perioperative dynamic changes remains insufficiently characterized. This study aimed to evaluate the prognostic significance of both preoperative inflammatory biomarkers and their perioperative alterations in patients undergoing curative-intent surgical resection for NSCLC.MethodsWe conducted a retrospective cohort study of 368 consecutive patients who underwent surgical resection for pathologically confirmed NSCLC at our institution between January 2022 and December 2024. Preoperative blood samples were analyzed for complete blood count, C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6). Inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) were calculated. Perioperative changes (Δ) were determined from postoperative day 1 values. Primary endpoints were disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) at 12 months. Kaplan-Meier analysis with log-rank tests and Cox proportional hazards regression were employed for survival analysis.ResultsThe median follow-up was 12.0 months. At 12 months, the DFS, RFS, and OS rates were 48.4%, 63.9%, and 75.0%, respectively. In univariate analysis, elevated NLR [≥2.78; hazard ratio (HR) =1.97, 95% confidence interval (CI): 1.48–2.62, P<0.001], elevated SII (≥585; HR =1.81, 95% CI: 1.35–2.42, P<0.001), low PNI (<47.8; HR =1.70, 95% CI: 1.28–2.27, P<0.001), elevated IL-6 (≥9.8 pg/mL; HR =1.71, 95% CI: 1.19–2.46, P=0.004), and high ΔNLR (≥7.8; HR =2.07, 95% CI: 1.50–2.85, P<0.001) were significantly associated with inferior DFS. Multivariate analysis identified advanced stage (IIB-IIIA; HR =1.41, 95% CI: 1.02–1.95, P=0.04), low PNI (HR =1.62, 95% CI: 1.21–2.17, P=0.001), elevated IL-6 (HR =1.67, 95% CI: 1.15–2.41, P=0.007), and high ΔNLR (HR =1.69, 95% CI: 1.15–2.50, P=0.008) as independent prognostic factors for DFS. The combined inflammatory index achieved superior discriminatory performance [area under the curve (AUC) =0.712] compared with individual markers.ConclusionsPerioperative inflammatory biomarkers, particularly the combination of preoperative PNI, IL-6, and perioperative ΔNLR, provide robust prognostic stratification in surgically resected NSCLC. Integration of these readily accessible biomarkers into clinical decision-making may facilitate personalized surveillance strategies and adjuvant therapy selection.Keywords: Non-small cell lung cancer (NSCLC), inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI), interleukin-6 (IL-6) Highlight box Key findings • Preoperative prognostic nutritional index (PNI), interleukin-6 (IL-6), and perioperative Δ neutrophil-to-lymphocyte ratio (NLR) were independent prognostic factors for disease-free survival in resected non-small cell lung cancer (NSCLC); a combined inflammatory index [NLR + systemic immune-inflammation index (SII) + PNI + IL-6 + ΔNLR] achieved superior discriminatory performance (area under the curve =0.712), with video-assisted thoracoscopic surgery (VATS) associated with a significantly attenuated postoperative inflammatory response versus open thoracotomy. What is known and what is new? • Preoperative inflammatory indices (NLR, SII, PNI) carry prognostic value in resected NSCLC, but prior studies relied on static measurements. • Perioperative ΔNLR provides independent prognostic information beyond baseline values; surgical approach (VATS vs. thoracotomy) significantly modulates the magnitude of perioperative inflammation. What is the implication, and what should change now? • Routine perioperative assessment of PNI, IL-6, and ΔNLR should be incorporated into postoperative risk stratification to guide surveillance and adjuvant therapy decisions. • Multiparametric inflammatory scoring should replace single-biomarker approaches in clinical algorithms for surgically resected NSCLC. Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases (1). Surgical resection offers the best prospect for cure in early-stage disease, yet a substantial proportion of patients experience disease recurrence despite curative-intent surgery (2). Accurate prognostic stratification is therefore essential for identifying high-risk patients who may benefit from intensified surveillance or adjuvant therapeutic interventions. The tumor microenvironment is characterized by a complex interplay between malignant cells and host immune responses, with systemic inflammation emerging as a critical determinant of cancer progression and metastasis (3,4). Circulating inflammatory markers derived from routine laboratory tests have garnered considerable attention as accessible and cost-effective prognostic indicators. The neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) integrate multiple components of the inflammatory cascade and nutritional status, reflecting the balance between pro-tumor inflammation and anti-tumor immunity (5-7). Recent meta-analyses have confirmed the prognostic value of preoperative inflammatory indices in NSCLC, demonstrating associations with OS, disease-free survival (DFS), and postoperative complications (8-10). However, the majority of studies have focused exclusively on static preoperative measurements, potentially overlooking the dynamic inflammatory response induced by surgical trauma. The perioperative period represents a critical window during which the magnitude of systemic inflammation may influence tumor cell dissemination and dormant micrometastatic activation (11,12). Emerging evidence suggests that perioperative changes in inflammatory biomarkers (Δ-indices) may provide incremental prognostic information beyond baseline values (13,14). Notably, video-assisted thoracoscopic surgery (VATS) has been associated with attenuated inflammatory responses compared with open thoracotomy, potentially conferring immunological advantages (15,16). Furthermore, acute-phase reactants including C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) offer complementary insights into systemic inflammation that may enhance risk stratification when combined with cell-ratio indices (17,18). In this context, we conducted a comprehensive evaluation of perioperative inflammatory biomarkers in patients undergoing surgical resection for NSCLC at a single institution. Our objectives were threefold: (I) to assess the prognostic significance of preoperative inflammatory indices and acute-phase markers; (II) to evaluate the additional predictive value of perioperative dynamic changes; and (III) to develop an integrated inflammatory scoring system for clinical risk stratification. We present this article in accordance with the REMARK reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/rc). Methods Study design and patient selection This retrospective cohort study included consecutive patients who underwent surgical resection for histopathologically confirmed NSCLC at the Department of Thoracic Surgery, The First Hospital of Putian, Putian, Fujian, China, between January 1, 2022, and December 30, 2024. Inclusion criteria were: (I) pathologically confirmed primary NSCLC; (II) curative-intent surgical resection including wedge resection, segmentectomy/subsegmentectomy, lobectomy, or sleeve resection; (III) complete preoperative and postoperative laboratory data; and (IV) minimum follow-up of 12 months or documented outcome event. Exclusion criteria comprised: (I) neoadjuvant chemotherapy or radiotherapy; (II) concurrent malignancy or history of other cancers within 5 years; (III) active infection or chronic inflammatory conditions; (IV) immunosuppressive therapy; and (V) incomplete medical records. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Institutional Review Board of The First Hospital of Putian (No. 2026006). Informed consent was waived in this retrospective study. Laboratory measurements Preoperative blood samples were obtained within 7 days prior to surgery following overnight fasting. Postoperative specimens were collected on postoperative day 1 (POD1). Complete blood count, including white blood cell differential, was performed using an automated hematology analyzer (Mindray BC-7500, Shenzhen, China). CRP was measured by nephelometry (Siemens BN II System, Erlangen, Germany). Procalcitonin and IL-6 were quantified using chemiluminescent immunoassay (Unicel Wan200+, Shanghai, China). The following inflammatory indices were calculated from peripheral blood parameters: ❖ NLR = neutrophil count / lymphocyte count ❖ NLR = neutrophil count / lymphocyte count ❖ PLR = platelet count / lymphocyte count ❖ PLR = platelet count / lymphocyte count ❖ Lymphocyte-to-monocyte ratio (LMR) = lymphocyte count / monocyte count ❖ Lymphocyte-to-monocyte ratio (LMR) = lymphocyte count / monocyte count ❖ SII = platelet × neutrophil / lymphocyte ❖ SII = platelet × neutrophil / lymphocyte ❖ Systemic inflammation response index (SIRI) = neutrophil × monocyte / lymphocyte ❖ Systemic inflammation response index (SIRI) = neutrophil × monocyte / lymphocyte ❖ PNI = 10 × albumin (g/dL) + 0.005 × lymphocyte count (/µL) ❖ PNI = 10 × albumin (g/dL) + 0.005 × lymphocyte count (/µL) ❖ C-reactive protein to albumin ratio (CAR) = CRP (mg/L) / albumin (g/L) ❖ C-reactive protein to albumin ratio (CAR) = CRP (mg/L) / albumin (g/L) Perioperative changes (Δ-values) were defined as POD1 value minus preoperative value for each marker. Clinical outcomes The primary endpoints were DFS, RFS, and OS at 12 months. DFS was defined as the interval from surgery to disease recurrence (local or distant), death from any cause, or last follow-up. RFS was measured from surgery to documented disease recurrence or last follow-up, with deaths censored. OS was calculated from the date of surgery to death from any cause or last contact. Secondary endpoints included postoperative complications and hospital length of stay. Follow-up evaluations were conducted at 3-month intervals during the first year, consisting of physical examination, chest computed tomography, and tumor marker assessment. Additional imaging studies were performed when clinically indicated. Statistical analysis Continuous variables were expressed as mean ± standard deviation or median with interquartile range (IQR), depending on distribution normality assessed by the Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. Between-group comparisons utilized the independent t-test, Mann-Whitney U test, or chi-square test as appropriate. Optimal cut-off values for inflammatory biomarkers were determined by receiver operating characteristic (ROC) curve analysis using the Youden index (J = sensitivity + specificity − 1). The area under the curve (AUC) was calculated to assess discriminatory performance. Survival curves were constructed using the Kaplan-Meier method and compared by log-rank test. Cox proportional hazards regression was employed for univariate and multivariate analyses. Variables with P<0.10 in univariate analysis were entered into the multivariate model. The proportional hazards assumption was verified using Schoenfeld residuals. Results were expressed as hazard ratios (HR) with 95% confidence intervals (CIs). Model discrimination was evaluated using Harrell’s concordance index (C-index). All statistical analyses were performed using Python 3.11 with the lifelines and scikit-learn packages. Two-sided P values <0.05 were considered statistically significant. Results Patient characteristics A total of 368 patients met the inclusion criteria and were enrolled in the final analysis. The baseline clinicopathological characteristics are summarized in Table 1. The mean age was 61.56±9.81 years, and 223 patients (60.6%) were male. Regarding smoking history, 127 patients (34.5%) were never-smokers, 149 (40.5%) were former smokers, and 92 (25.0%) were current smokers. Table 1Baseline clinicopathological characteristics of patients (n=368)CharacteristicValueAge (years) 61.56±9.81Sex Male223 (60.6) Female145 (39.4)BMI (kg/m2)23.18±3.42Smoking status Never127 (34.5) Former149 (40.5) Current92 (25.0)Hypertension142 (38.6)Diabetes mellitus57 (15.5)COPD86 (23.4)Histology Adenocarcinoma237 (64.4) Squamous cell carcinoma105 (28.5) Other26 (7.1)Pathological stage (8th TNM) IA108 (29.3) IB94 (25.5) IIA68 (18.5) IIB55 (14.9) IIIA43 (11.7)Tumor size (cm)2.68 (1.85–3.72)Lymphovascular invasion116 (31.5)Differentiation Well83 (22.6) Moderate189 (51.4) Poor96 (26.1)Surgical approach VATS252 (68.5) Thoracotomy116 (31.5)Procedure type Wedge resection42 (11.4) Segmentectomy64 (17.4) Lobectomy234 (63.6) Sleeve resection28 (7.6)Data are presented as n (%), mean ± standard deviation, or median (interquartile range). BMI, body mass index; COPD, chronic obstructive pulmonary disease; TNM, tumor-node-metastasis; VATS, video-assisted thoracoscopic surgery. Baseline clinicopathological characteristics of patients (n=368) Data are presented as n (%), mean ± standard deviation, or median (interquartile range). BMI, body mass index; COPD, chronic obstructive pulmonary disease; TNM, tumor-node-metastasis; VATS, video-assisted thoracoscopic surgery. The predominant histological subtype was adenocarcinoma (237 patients, 64.4%), followed by squamous cell carcinoma (105 patients, 28.5%) and other types (26 patients, 7.1%). The distribution of pathological stages was: IA (108 patients, 29.3%), IB (94 patients, 25.5%), IIA (68 patients, 18.5%), IIB (55 patients, 14.9%), and IIIA (43 patients, 11.7%). Lymphovascular invasion was present in 116 patients (31.5%). Inflammatory biomarker profiles stratified by pathological stage are summarized in Table S1. Across all five stage subgroups (IA through IIIA), a mild and non-monotonic variation in preoperative inflammatory markers was observed; however, none of the biomarkers demonstrated statistically significant differences across stage groups (NLR: P=0.08; SII: P=0.20; PNI: P=0.80; IL-6: P=0.21; CRP: P=0.91; Kruskal-Wallis test). This finding indicates that the prognostic utility of these markers is not a surrogate for staging information, and is consistent with their demonstrated independent prognostic significance after adjustment for stage in multivariate Cox regression. The majority of procedures were performed via VATS approach (252 patients, 68.5%), with lobectomy being the most common procedure type (234 patients, 63.6%). Other procedures included segmentectomy (64 patients, 17.4%), wedge resection (42 patients, 11.4%), and sleeve resection (28 patients, 7.6%). Preoperative and postoperative inflammatory parameters The preoperative inflammatory profiles are presented in Table 2. The median preoperative NLR was 2.63 (IQR: 1.91–3.46), SII was 586.44 (IQR: 408.71–805.74), and PNI was 49.30 (IQR: 45.74–52.73). The median preoperative CRP and IL-6 levels were 3.09 mg/L (IQR: 1.73–5.86) and 4.14 pg/mL (IQR: 2.70–7.25), respectively. Table 2Preoperative and postoperative inflammatory parametersParameterPreoperativePOD1WBC (×109/L)6.82 (5.48–8.45)12.56 (9.85–15.78)Neutrophil (×109/L)4.25 (3.28–5.46)10.45 (7.92–13.56)Lymphocyte (×109/L)1.62 (1.25–2.08)0.86 (0.65–1.12)Monocyte (×109/L)0.58 (0.42–0.78)0.82 (0.62–1.08)Platelet (×109/L)228.45±58.32218.65±52.45Hemoglobin (g/L)128.56±16.25–CRP (mg/L)3.09 (1.73–5.86)78.45 (48.32–125.68)PCT (ng/mL)0.08 (0.05–0.14)0.52 (0.28–0.95)IL-6 (pg/mL)4.14 (2.70–7.25)165.32 (95.45–285.67)Albumin (g/L)41.18±4.02–NLR2.63 (1.91–3.46)10.52 (7.85–14.28)PLR139.95 (104.56–183.33)252.45 (185.67–342.56)LMR2.59 (1.87–3.63)1.05 (0.72–1.45)SII (×109/L)586.44 (408.71–805.74)2,456.78 (1685.45–3,528.92)SIRI1.52 (0.98–2.25)9.85 (6.45–14.56)PNI49.30 (45.74–52.73)–CAR0.075 (0.042–0.145)–Values are presented as median (interquartile range) or mean ± standard deviation. CAR, C-reactive protein to albumin ratio; CRP, C-reactive protein; IL-6, interleukin-6; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; POD1, postoperative day 1; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; WBC, white blood cell. Preoperative and postoperative inflammatory parameters Values are presented as median (interquartile range) or mean ± standard deviation. CAR, C-reactive protein to albumin ratio; CRP, C-reactive protein; IL-6, interleukin-6; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; POD1, postoperative day 1; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index; WBC, white blood cell. Postoperative inflammatory markers demonstrated significant elevation from baseline values. On POD1, median NLR increased to 10.52 (IQR: 7.85–14.28), CRP rose to 78.45 mg/L (IQR: 48.32–125.68), and IL-6 increased to 165.32 pg/mL (IQR: 95.45–285.67). The magnitude of postoperative inflammatory response differed significantly between surgical approaches, with VATS-treated patients exhibiting lower POD1 values compared with thoracotomy patients for NLR (9.85 vs. 12.45, P=0.002), CRP (68.25 vs. 105.78 mg/L, P<0.001), and IL-6 (142.56 vs. 215.89 pg/mL, P<0.001). Survival outcomes At a median follow-up of 12.0 months, 190 patients (51.6%) experienced DFS events, including 133 recurrences (36.1%) and 92 deaths (25.0%). The 12-month DFS, RFS, and OS rates for the entire cohort were 48.4%, 63.9%, and 75.0%, respectively. Kaplan-Meier survival analysis stratified by inflammatory biomarker status revealed significant differences in DFS (Figure 1). Patients with high NLR (≥2.78) demonstrated significantly inferior 12-month DFS compared with the low NLR group (39.2% vs. 55.8%, log-rank P<0.001). Similarly, patients with high SII (≥585) had reduced 12-month DFS (40.5% vs. 57.2%, P<0.001), and those with low PNI (<47.8) exhibited poorer outcomes (41.8% vs. 53.6%, P<0.001). Notably, patients with elevated perioperative ΔNLR (≥7.8) showed markedly worse 12-month DFS (38.5% vs. 60.2%, P<0.001). Kaplan-Meier curves for disease-free survival stratified by inflammatory biomarker status. (A) NLR; (B) SII; (C) PNI; (D) IL-6; (E) ΔNLR; (F) CRP. Patients were dichotomized according to optimal cut-off values determined by ROC analysis. CRP, C-reactive protein; IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; ROC, receiver operating characteristic; SII, systemic immune-inflammation index. To address the homogeneity concern, a pre-specified subgroup analysis was conducted in stage I adenocarcinoma patients, representing a clinically relevant and biologically uniform cohort (Figure S1). Among the 136 stage I (IA + IB) adenocarcinoma patients (IA: 81, IB: 55), elevated ΔNLR (≥7.8) was significantly associated with inferior 12-month DFS (38.8% vs. 69.6%, log-rank P=0.0003), RFS (52.5% vs. 82.1%, P=0.0005), and OS (68.8% vs. 85.7%, P=0.03) (Figure S1). Preoperative NLR (≥2.78; P=0.003) and SII (≥585; P=0.004) also retained significant prognostic associations with DFS in this subgroup, whereas PNI (P=0.10) and IL-6 (P=0.23) showed non-significant trends, likely reflecting reduced statistical power in this smaller, more homogeneous cohort. These findings demonstrate that the prognostic utility of ΔNLR, and to a lesser extent NLR and SII, is preserved within stage I adenocarcinoma, reinforcing the clinical applicability of our perioperative biomarker risk stratification approach. Cox regression analysis Univariate Cox regression analysis identified several factors significantly associated with DFS (Table 3). Among preoperative inflammatory markers, elevated NLR (HR =1.97, 95% CI: 1.48–2.62, P<0.001), elevated PLR (HR =1.38, 95% CI: 1.04–1.83, P=0.03), elevated SII (HR =1.81, 95% CI: 1.35–2.42, P<0.001), elevated SIRI (HR =1.47, 95% CI: 1.05–2.05, P=0.03), low PNI (HR =1.70, 95% CI: 1.28–2.27, P<0.001), elevated IL-6 (HR =1.71, 95% CI: 1.19–2.46, P=0.004), and elevated Glasgow prognostic score (GPS) (HR =1.49, 95% CI: 1.07–2.08, P=0.02) were significantly associated with inferior DFS. The perioperative change in NLR (ΔNLR ≥7.8) emerged as the strongest univariate predictor (HR =2.07, 95% CI: 1.50–2.85, P<0.001). Table 3Univariate and multivariate Cox regression analysis for disease-free survivalVariableUnivariate analysisMultivariate analysisHR95% CIPHR95% CIPAge (per year)1.000.98–1.010.581.000.99–1.010.99Male sex0.780.59–1.040.090.760.57–1.020.07Stage IIB-IIIA1.300.94–1.790.111.411.02–1.950.04*LVI1.110.82–1.500.521.120.82–1.510.48NLR ≥2.781.971.48–2.62<0.001***1.400.96–2.030.08PLR ≥1521.381.04–1.830.03*–––SII ≥5851.811.35–2.42<0.001***1.030.71–1.510.87SIRI ≥1.181.471.05–2.050.03*–––PNI <47.81.701.28–2.27<0.001***1.621.21–2.170.001**CRP ≥8.5 mg/L1.130.75–1.700.56–––IL-6 ≥9.8 pg/mL1.711.19–2.460.004**1.671.15–2.410.007**GPS ≥11.491.07–2.080.02*–––ΔNLR ≥7.82.071.50–2.85<0.001***1.691.15–2.500.008***, P<0.05; **, P<0.01; ***, P<0.001. CI, confidence interval; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; HR, hazard ratio; IL-6, interleukin-6; LVI, lymphovascular invasion; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index. Univariate and multivariate Cox regression analysis for disease-free survival *, P<0.05; **, P<0.01; ***, P<0.001. CI, confidence interval; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; HR, hazard ratio; IL-6, interleukin-6; LVI, lymphovascular invasion; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index. In multivariate analysis adjusting for age, sex, stage, and lymphovascular invasion, four variables retained independent prognostic significance for DFS: advanced stage (IIB-IIIA; HR =1.41, 95% CI: 1.02–1.95, P=0.04), low PNI (HR =1.62, 95% CI: 1.21–2.17, P=0.001), elevated IL-6 (HR =1.67, 95% CI: 1.15–2.41, P=0.007), and high ΔNLR (HR =1.69, 95% CI: 1.15–2.50, P=0.008). The multivariate model achieved a C-index of 0.649, indicating moderate discriminatory ability. Kaplan-Meier analysis for OS demonstrated that patients with elevated NLR, SII, and IL-6 had significantly inferior 12-month survival rates compared with their respective low-risk counterparts (Figure 2). For OS, multivariate analysis identified elevated NLR (HR =2.04, 95% CI: 1.17–3.57, P=0.01) as an independent prognostic factor, with a model C-index of 0.651. The results of the forest plot analysis for DFS are depicted in Figure 3. Kaplan-Meier curves for overall survival stratified by inflammatory biomarker status. (A) NLR; (B) SII; (C) IL-6. Patients were dichotomized according to optimal cut-off values. IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; SII, systemic immune-inflammation index. Forest plot illustrating hazard ratios from multivariate Cox proportional hazards regression analysis for disease-free survival. Red squares indicate statistically significant associations (P<0.05); gray squares indicate non-significant associations. CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index. ROC analysis and combined inflammatory index ROC curve analysis was performed to evaluate the discriminatory performance of inflammatory biomarkers for predicting DFS events (Figure 4). Among individual preoperative markers, NLR demonstrated the highest AUC (0.625), followed by SII (0.604), PNI (0.596), and IL-6 (0.543). The perioperative ΔNLR exhibited comparable discriminatory ability (AUC=0.619). ROC curves for predicting disease-free survival events. (A) Preoperative inflammatory biomarkers including NLR, SII, PNI, IL-6, and CRP. (B) Perioperative ΔNLR and the combined inflammatory index incorporating NLR, SII, IL-6, PNI, and ΔNLR. AUC, area under the curve; CRP, C-reactive protein; IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; ROC, receiver operating characteristic; SII, systemic immune-inflammation index. A combined inflammatory index incorporating NLR, SII, IL-6, PNI, and ΔNLR was constructed using logistic regression. This composite model achieved superior discriminatory performance (AUC =0.712) compared with any single marker, suggesting additive prognostic value from the integration of multiple inflammatory parameters. Perioperative inflammatory response by surgical approach The perioperative changes in inflammatory markers stratified by surgical approach are illustrated in Figure 5. VATS-treated patients exhibited a significantly attenuated postoperative inflammatory response compared with thoracotomy patients. The mean ΔNLR was 6.85±3.42 in the VATS group versus 9.78±4.56 in the thoracotomy group (P<0.001). Similarly, ΔCRP (65.45±28.32 vs. 98.56±42.18 mg/L, P<0.001) and ΔIL-6 (138.25±68.45 vs. 198.67±95.32 pg/mL, P<0.001) were significantly lower in VATS-treated patients. Perioperative changes in inflammatory markers stratified by surgical approach. (A) NLR; (B) IL-6; (C) CRP. VATS-treated patients demonstrated significantly attenuated postoperative inflammatory responses compared with thoracotomy patients. CRP, C-reactive protein; IL-6, interleukin-6; NLR, neutrophil-to-lymphocyte ratio; POD1, postoperative day 1; VATS, video-assisted thoracoscopic surgery. Discussion In this retrospective cohort study of 368 patients undergoing surgical resection for NSCLC, we demonstrated that perioperative inflammatory biomarkers provide meaningful prognostic information for DFS, RFS, and OS. Our findings extend the existing literature by highlighting the independent prognostic value of the perioperative change in NLR (ΔNLR) beyond traditional preoperative markers, and by characterizing the differential inflammatory response patterns between VATS and open thoracotomy approaches. The association between systemic inflammation and cancer prognosis is well-established and mechanistically plausible (19,20). Neutrophils promote tumor progression through the release of reactive oxygen species, matrix metalloproteinases, and pro-angiogenic factors, while lymphocytes mediate anti-tumor immune surveillance (21). The NLR thus reflects the balance between tumor-promoting and tumor-suppressing immune responses. Our findings of elevated NLR portending inferior survival align with the meta-analytic evidence reported by Cao et al., who demonstrated pooled HRs of 1.51 and 1.58 for OS and DFS, respectively, in early-stage resected NSCLC (8). The SII, which incorporates platelet counts in addition to neutrophil and lymphocyte populations, captures the multidimensional nature of cancer-related inflammation (22). Platelets facilitate metastasis by protecting circulating tumor cells from immune destruction and promoting vascular adhesion (23). Our observation that elevated SII (≥585) was associated with reduced DFS (HR =1.81) corroborates the findings of Huang et al.’s meta-analysis, which reported a pooled HR of 1.75 for elevated SII in NSCLC (9). The PNI represents an integrated assessment of nutritional and immunological status, combining serum albumin—a marker of protein synthesis capacity and inflammatory response—with lymphocyte count (24). Low PNI has been consistently associated with adverse outcomes across multiple malignancies, including NSCLC (10,25). Our multivariate analysis confirmed PNI as an independent prognostic factor (HR =1.62, P=0.001), suggesting that preoperative nutritional optimization may represent a modifiable target for improving surgical outcomes. The incorporation of IL-6 measurements adds molecular specificity to the inflammatory assessment. As a pleiotropic cytokine central to the acute-phase response, IL-6 directly stimulates tumor cell proliferation, angiogenesis, and chemoresistance via STAT3 signaling (26,27). Our finding that preoperative IL-6 ≥9.8 pg/mL independently predicted inferior DFS (HR =1.67, P=0.007) supports its integration into prognostic models, particularly given the availability of IL-6-targeted therapeutics such as tocilizumab (28). A distinctive contribution of our study is the demonstration that the perioperative ΔNLR provides prognostic information independent of baseline values. The surgical stress response triggers a cascade of neuroendocrine and immunological alterations, including catecholamine release, cytokine production, and leukocyte mobilization (29). An exaggerated inflammatory response to surgery may indicate diminished physiological reserve or heightened tumor-host interaction intensity, potentially facilitating the establishment of distant metastases from circulating tumor cells shed during surgical manipulation (30). Our observation of differential inflammatory responses between VATS and thoracotomy aligns with the accumulating evidence favoring minimally invasive approaches in lung cancer surgery (15,16). Although systematic operative time data were not captured in the present retrospective dataset, the established literature demonstrates a well-established dose-response relationship between surgical duration and perioperative cytokine release, including IL-6 and other acute-phase mediators (29), underscoring the biological plausibility of operative time as a modulator of perioperative inflammatory magnitude. Future prospective studies should formally quantify this relationship in the NSCLC surgical context. The attenuated postoperative inflammation with VATS may translate into preserved anti-tumor immunity during the vulnerable perioperative period, though long-term oncological equivalence has been established in randomized trials (31). Future studies should investigate whether the immunological advantages of minimally invasive surgery are preferentially beneficial in patients with elevated baseline inflammatory markers. The combined inflammatory index achieving an AUC of 0.712 demonstrates the complementary nature of multiple biomarkers and underscores the complexity of cancer-associated inflammation. Single-marker approaches may fail to capture the multifaceted inflammatory milieu, whereas integrated models provide a more comprehensive assessment. This finding is consistent with recent trends toward composite inflammatory-nutritional scores such as the Prognostic Immune-Inflammatory-Nutritional (PIIN) score reported by Gu et al. (32). Several clinical implications emerge from our findings. First, preoperative measurement of NLR, SII, PNI, and IL-6 can identify patients at elevated risk of recurrence who may benefit from enhanced surveillance protocols or consideration of adjuvant therapy. Second, excessive perioperative inflammatory response (ΔNLR ≥7.8) warrants attention as an indicator of potential adverse outcomes. Third, the superiority of the combined index suggests that multiparametric risk stratification should be incorporated into clinical decision-making algorithms. This study has several limitations. The retrospective single-center design introduces potential selection bias and limits generalizability. The 12-month follow-up period, while capturing early recurrence patterns, is insufficient to characterize late recurrence events and long-term survival outcomes, particularly for stage I NSCLC where recurrences may occur beyond 3–5 years. Extended follow-up studies with a minimum of 5-year observation are warranted to validate the long-term prognostic significance of perioperative inflammatory biomarkers and to evaluate whether early inflammatory risk stratification translates into durable survival benefits. The cut-off values derived from our cohort require external validation before clinical implementation. Additionally, we did not assess molecular markers such as EGFR mutation or PD-L1 expression, which may interact with inflammatory profiles to influence prognosis. Conclusions In conclusion, perioperative inflammatory biomarkers provide robust prognostic stratification in surgically resected NSCLC. Preoperative PNI and IL-6, along with the perioperative ΔNLR, emerged as independent predictors of DFS. The combination of multiple inflammatory markers achieved superior discriminatory performance compared with individual indices. Integration of these readily accessible, cost-effective biomarkers into clinical practice may facilitate personalized risk assessment and therapeutic decision-making in patients undergoing surgical resection for NSCLC. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Institutional Review Board of The First Hospital of Putian (No. 2026006). Informed consent was waived in this retrospective study. Footnotes Reporting Checklist: The authors have completed the REMARK reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/rc Funding: None. Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/dss References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/prf Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0664/dss